Lipid signalling in disease by Wymann, Matthias P. & Schneiter, Roger
Lipids have long since been recognized as signalling 
molecules that have the capacity to trigger profound 
physiological responses. Slow-reacting substance of 
anaphylaxis (SRS-A), now known to belong to the group 
of cysteinyl leukotrienes, was identified as early as 1930 
(REF. 1); at about the same time, the vasodilating actions 
of prostaglandins were described2. Subsequently, arachi-
donic acid was identified as the source of leukotrienes 
and prostaglandins (BOX 1), a discovery that has led to 
our current understanding of eicosanoid signalling3, 
and taught us that one and the same signalling lipid 
can provoke different cellular responses, depending on 
the precise cell type and underlying signalling network 
present in the target cell.
The study of the lipid components of cellular 
membranes, and in particular the turnover of phos-
phoinositides, culminated in the 1980s with the dis-
covery that phosphatidylinositol-4,5-bisphosphate 
(PtdIns(4,5)P2) could be hydrolysed by phospholipase C
(PLC) to diacylglycerol (DAG) and inositol-1,4,5-tris-
phosphate (Ins(1,4,5)P3). Both products were identified 
as second messengers that trigger the activation of pro-
tein kinase C (PKC; REF. 4) and the release of Ca2+ from 
internal stores, respectively. In parallel, inositol and 
phosphoinositide kinases have been identified; these 
enzymes generate a huge repertoire of soluble inositol 
polyphosphates and membrane polyphosphoinositide 
lipids. Phosphoinositide 3-kinase (PI3K), for example, 
which is regulated by cell-surface receptors, promotes 
the formation of phosphatidylinositol-3,4,5-trisphos-
phate (PtdIns(3,4,5)P3), a signalling lipid that modulates 
cell growth, proliferation and motility5,6. Interestingly, 
nature has used several possible variations of the inosi-
tol head group to create highly specific docking sites for 
lipid-binding proteins — effector proteins that trigger 
signalling cascades or enzymes that further modify these 
lipids (BOX 2; see the review by Lemmon in this issue). 
Phosphoinositides have, therefore, gained importance 
as localization tags that are involved in the organization 
of membrane-bound signalling complexes7.
Ceramides and sphingosines are lipids that have 
pro-apoptotic and antiproliferative actions8; when 
phosphorylated by lipid kinases, however, sphingosine 
is converted into sphingosine-1-phosphate (S1P), which 
promotes cell growth and proliferation by a still poorly 
understood intracellular action as well as by extracellu-
lar signalling through a set of different G protein-coupled
receptors (GPCRs) 9–11 (BOX 3; see the review by Hannun 
and Obeid in this issue). Another lipid that is released 
from cells, lysophosphatidic acid (LPA), also functions in 
an autocrine and paracrine manner by binding to a fam-
ily of GPCRs12,13. LPA, together with specific eicosanoids, 
can additionally modulate gene expression by binding 
to lipid-sensing transcription activators, such as the 
peroxisome proliferator-activated receptors (PPARs)14,15
(BOX 4).
Imbalances of these major lipid signalling pathways 
contribute to disease progression in chronic inflamm-
ation, autoimmunity, allergy, cancer, atherosclerosis, 
hypertension, heart hypertrophy, metabolic and degen-
erative diseases, among others (FIG. 1). Owing to their 
complexity, these pathways are mostly studied and 
reviewed in isolation. However, many of these signalling 
lipids, their modifying enzymes and downstream targets 
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disease, and discusses emerging strategies for therapeutic intervention.
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are common to multiple lipid signalling pathways, 
resulting in the formation of highly interconnected 
lipid signalling networks. As a consequence, many lipid 
signalling pathways are deregulated in different disease 
conditions. This review attempts to integrate the role of 
lipid signalling networks in inflammation, cancer and 
metabolic syndrome. Owing to the focus on integration, 
an in-depth discussion of each individual lipid signal-
ling pathway is beyond the scope of this review. We will 
also provide a brief overview of strategies that are cur-
rently being used to pharmacologically manipulate these 
lipid signalling networks. The commonality of various 
different signalling components means that different 
diseases share common points of intervention — this has 
important consequences for therapy, as will be discussed 
(see also the accompanying Poster entitled ‘Targeting 
lipid signalling in disease’; URL in the box at the end 
of the article).
Lipid signalling in inflammation
Modulation of the levels and/or behaviour of lipids 
that are involved in promoting inflammation has been 
practised for centuries. Early records indicate that a brew 
of willow tree leaves was used by Hippocrates around 
400 bc to relieve pain and fever. Many centuries later, 
this led from the clinical use of aspirin (synthesized 
by Felix Hoffmann at Bayer in 1897) to the develop-
ment of modern non-steroidal anti-inflammatory 
drugs (NSAIDs) and highly selective cyclooxygenase-2
(COX2) inhibitors.
Box 1 | From phospholipids to eicosanoid signalling
The production of eicosanoids is initiated by the release of C20-polyunsaturated fatty acids, such as arachidonic acid 
(AA, C20:4), from phospholipids (X stands for a phospholipid headgroup; see figure) or diacylglycerol (not shown; see 
BOX 2). This hydrolysis is catalysed by cytosolic phospholipase A2 (cPLA2). Ca2+-induced cPLA2 lipase action is the rate-
limiting step in eicosanoid formation, and cells lacking cPLA2 are generally devoid of eicosanoids. Liberated fatty acids
are then stereospecifically oxygenated either through the cyclic prostaglandin synthase pathway (prostaglandin H2 
synthase (PGH2S), including cyclooxygenase (COX) activity) or through the linear lipoxygenase-dependent pathway 
(5-lipoxygenase; 5-LO), and are thus converted into one of four families of eicosanoids: the prostaglandins (PGs), 
prostacyclins, thromboxanes (TXs) and leukotrienes.
Eicosanoids have a short half-life, ranging from seconds to minutes. Their prime mode of action is mediated by binding 
to specific G protein-coupled receptors (GPCRs), many of which have been identified recently, enabling the rational 
development of specific receptor agonists and antagonists (see the accompanying Poster entitled ‘Targeting lipid 
signalling in disease’). Eicosanoids can also bind to nuclear receptors. Eicosanoid signalling pathways are complex and are 
generally implicated in tissue homeostasis and/or inflammation. Prostanoids that are derived from W6 unsaturated fatty 
acids, such as AA, tend to give rise to the production of inflammatory mediators, whereas W3 unsaturated fatty acids are 
a source for anti-inflammatory and homeostatic prostanoids.
In addition, the lysolipids that are produced by the action of cPLA2 might themselves exert signalling functions and can 
be further processed: for example, when lysophosphatidylcholine (lyso-PC) is converted to platelet-activating factor 
(PAF, alkyl-acetyl phosphatidylcholine), which also supports inflammation. Anti-inflammatory drugs such as aspirin and 
other non-steroidal anti-inflammatory drugs (NSAIDs) function by blocking the cyclooxygenase-catalysed synthesis of 
prostanoids (prostacyclins, PGs and TXs)137,138.
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Players in inflammation. Chronic inflammation, auto-
immunity and allergy arise from disturbances in vital 
host defence mechanisms. Lymphocytes detect antigens 
through T-cell and B-cell receptors (TCRs and BCRs), 
whereas immunoglobulin (Ig) receptors engage in 
neutrophil-dependent phagocytosis of foreign particles 
and in the activation of mast cells. Mast cells, macro-
phages and neutrophils can unleash irreversible tissue 
destruction. Independent of the cell type, immuno-
globulin receptors (IgG receptors (FcG	 in neutrophils 
and macrophages, IgE receptors (FcERI) in mast cells) 
couple to similar signal cascades that differ in the exact 
identity, but not functionality, of the protein kinases and 
adaptor proteins that are involved, and culminate in an 
increase in intracellular Ca2+ concentration ([Ca2+]i).
In mast cells and granulocytes, elevated [Ca2+]i initi-
ates the release of granule contents and the formation 
of prostaglandins, thromboxanes and leukotrienes, 
which is followed by the production of cytokines and 
chemokines. Although leukocytes (lymphocytes, mast 
cells, granulocytes, macrophages and neutrophils) 
have common features of activation, the activation of 
mast cells will be discussed as a representative example 
because lipid signalling has been investigated extensively 
in these cells.
From antigen receptors to PtdIns(4,5)P2 turnover.
Antigen–IgE complexes trigger the crosslinking of high-
affinity IgE receptors and their association with lipid rafts
on mast cells, initiating a cascade of protein tyrosine 
kinases. These phosphorylate immunoreceptor tyro-
sine-based activation motifs (ITAMs) on the cytosolic 
part of the IgE receptor and cause the translocation of 
the kinase Syk through its two Src-homology-2 (SH2)
Box 2 | Intracellular signalling by phosphoinositides
The biological versatility of phosphatidylinositol (PtdIns) 
derives from its unique ability to be reversibly 
phosphorylated at three distinct positions of the inositol 
headgroup. Single or combinatorial phosphorylation of 
the 3, 4 and 5 positions on the inositol ring of PtdIns can 
generate at least seven unique phosphoinositides, which 
have diverse roles in receptor-mediated signal 
transduction, cytoskeletal remodelling, nuclear events and 
membrane trafficking. Lipid kinases, phosphatases and 
lipases that produce and degrade these signalling lipids 
spatially and temporally control the biological activity of 
phosphoinositides. Phosphoinositides signal through 
cytosolic effector proteins that have phosphoinositide-
binding domains, which are frequently combined with 
additional modules that are involved in the formation of 
complex protein–protein and protein–lipid interaction 
networks7 (see the review by Lemmon in this issue).
The plasma-membrane-localized phosphatidylinositol-
4,5-bisphosphate (PtdIns(4,5)P2) represents a focal point in 
phosphoinositide-dependent signalling because it serves 
as the substrate for two powerful receptor-regulated 
signal-generating enzymes (see figure). Cleavage of 
PtdIns(4,5)P2 by phosphoinositide-specific phospholipase C
(PLC) produces two second messengers, membrane-
associated diacylglycerol (DAG) and the soluble inositol-
1,4,5-trisphosphate (Ins(1,4,5)P3) (see the review by Michell 
in this issue). Protein kinase C (PKC) docks through its C1 
domain onto DAG, whereas Ins(1,4,5)P3 stimulates the 
release of Ca2+ ions from the endoplasmic reticulum (ER).
Alternatively, PtdIns(4,5)P2 can be converted to PtdIns(3,4,5)P3 by the class I phosphoinositide 3-kinases (PI3Ks). 
PtdIns(3,4,5)P3 levels are negligible in resting cells, but can transiently and dramatically increase in response to growth-
factor stimulation to mediate a wide variety of effects, including cell proliferation, migration, chemotaxis, phagocytosis 
and macropinocytosis, differentiation, survival and metabolic changes. PtdIns(3,4,5)P3 functions by recruiting effectors 
that activate synergistic pathways. Prominent among these are guanine nucleotide-exchange factors and GTPase-
activating proteins, which regulate the actin cytoskeleton, and phosphoinositide-dependent protein kinase and protein 
kinase B (PKB/Akt), which cooperate in the activation of important signalling cascades, such as the mammalian target of 
rapamycin (mTOR) pathway.
PtdIns(3,4,5)P3 is dephosphorylated by two types of phosphatases: first, dephosphorylation at the 3 position by PTEN 
(phosphatase and tensin homologue deleted on chromosome ten) regenerates PtdIns(4,5)P2 and is the ‘off’ signal. Second, 
dephosphorylation by 5-phosphatases such as SHIP1 and SHIP2 (Src-homology-2 (SH2) domain-containing inositol 
5-phosphatase) generates PtdIns(3,4)P2, which shares some actions with PtdIns(3,4,5)P3 and can, for example, translocate 
PKB/Akt, but not Bruton’s protein tyrosine kinase (Btk; see FIG. 2), to the plasma membrane. Polyphosphoinositides 
regulate a wide range of effector proteins that harbour PH, FYVE, PX and ENTH domains139 (see also the review by 
Lemmon in this issue). Ras-GRP, Ras guanyl nucleotide-releasing protein.
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domains (see FIG. 2 and REF. 16). Further phosphorylation 
of membrane-anchored proteins (such as linker for activ-
ation of T cells (LAT) and non-T-cell activation linker 
(NTAL)) and soluble adaptor proteins (such as GAB2) 
starts a first wave of lipid signalling by recruitment of 
so-called class IA PI3K heterodimers that comprise the 
regulatory subunit p85 and catalytic subunit of PI3K 
(PI3Kc) (FIG. 2).
The catalytic subunit of PI3KD (p110D) has an 
important role downstream of the IgE receptor17, but 
it also relays signals from the B-cell receptor and, to a 
lesser extent, the T-cell receptor18. Elevation of levels of 
PtdIns(3,4,5)P3 by PI3K is crucial for the progression 
of antigen receptor signalling because the lipid recruits 
and activates proteins that contain pleckstrin homol-
ogy (PH) domains — among them, Bruton’s tyrosine 
kinase (Btk) and PLCG. Activation of PLCG through 
the generation of Ins(1,4,5)P3 causes Ca2+ release from 
internal stores. Usually, overstimulation of immune cells 
at low antigen concentrations is prevented by the SH2-
domain-containing inositol 5-phosphatase-1 (SHIP1; 
for a review see REF. 19), which reduces the levels of 
PtdIns(3,4,5)P3.
Through the second wave to the point of no return. If 
PtdIns(3,4,5)P3 levels remain high, phospholipase D 
(PLD) and sphingosine kinase (SphK) are activated, 
and release phosphatidic acid (PA) and S1P. S1P has 
been reported to act intracellularly on Ca2+ stores20, but 
a distinct intracellular receptor has not been identified 
to date21. Once Ca2+ stores are emptied, they signal to 
open store-operated Ca2+ channels (SOCCs) in the plasma 
membrane and trigger a massive influx of extracellular 
Ca2+. This influx is required to initiate the activation of 
Box 3 | Sphingolipid signalling from sphingomyelin to sphingosine-1-phosphate
Sphingolipids are characterized by the presence of a particular aliphatic aminoalcohol, sphingosine (also termed a long-
chain base), instead of the glycerol that is found in glycerolipids. The turnover of sphingolipids can yield potent signalling 
molecules. Cleavage of sphingomyelin by sphingomyelinase (SMase) generates ceramide, which promotes apoptosis, cell-
cycle arrest and cellular senescence (see REFS 140,141 and the review by Hannun and Obeid in this issue). Ceramide can 
be phosphorylated by ceramide kinase (CerK) to form ceramide-1-phosphate (C1P), which has mitogenic properties, 
antagonizes the pro-apoptotic action of ceramide and promotes inflammation41. Alternatively, ceramide can be cleaved 
by ceramidase to produce sphingosine, which again mediates apoptosis and cell-cycle arrest. Sphingosine can, in analogy 
to ceramide, be phosphorylated by one of two sphingosine kinases (SphK1 or -2) to form sphingosine-1-phosphate (S1P). 
Sphingosine kinases thus form a crucial part of the ‘sphingolipid rheostat’ to balance the pro-apoptotic actions of 
ceramide with the pro-survival action of S1P (see figure). S1P operates both intracellularly and extracellularly to function 
in cell survival, cell motility, cell proliferation and inflammation. The extracellular actions of S1P are mediated by members 
of the lysophospholipid receptor family of G protein-coupled receptors (S1P1–5; previously known as the Edg family of 
receptors). The nature of intracellular S1P receptors is still controversial, and intracellular S1P actions are probably also 
linked to ceramide levels that are regulated through de novo synthesis142. S1P is degraded by S1P lyase to form 
ethanolamine phosphate and hexadecanal.
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a plethora of Ca2+-sensitive signalling enzymes such as 
PKCs, ceramide kinase (CerK), cytosolic phospholipase 
A2 (cPLA2), 5-lipoxygenase (5-LO) and prostaglandin 
H2 synthase (PGH2S), and to release histamine from 
mast cell granulae.
The activation of cPLA2 by Ca2+-mediated transloca-
tion to the nuclear membrane is further supported by 
ceramide-1-phosphate (C1P; REF. 22), which is produced 
by CerK, and by the phosphorylation of cPLA2 by multi-
ple protein kinases23,24. Activated cPLA2 then releases 
arachidonic acid — the source of prostaglandins, leuko-
trienes and thromboxanes. These eicosanoids mediate 
the classical features of inflammation and promote a 
wide range of diseases from chronic inflammation, 
allergy, cardiovascular disease and obesity to cancer 
and more3,25. Eicosanoids26 and S1P11,27 act extracellu-
larly through GPCRs, and function in conjunction with 
chemokines, cytokines and histamine. These inflam-
matory mediators promote bronchial constriction, 
increased vascular permeability and diameter, and the 
invasion of leukocytes, which, when in excess, cause tis-
sue destruction in late allergy and inflammation19.
Dysregulated lipid signalling in cancer
In cancer that is derived from epithelial cells, early muta-
tions increase cell growth and proliferation, which results 
in hyperplasia and adenoma. Malignant and fatal tumours 
develop when the cells can undergo contact-independent 
growth, become motile and cross the basal lamina to form 
metastases. Although tumour-cell-autonomous activa-
tion steps are important in cancer progression, signals 
derived from the tumour or stroma that influence, for 
example, endothelial cells (to mediate angiogenesis) 
and immune cells (for example, to avoid recognition and 
destruction) are equally crucial. Here, we provide a 
simplified overview of the intracellular and extracellular 
lipid-derived signals that function in tumour growth, and 
provide some insight into current attempts to modulate 
deviations in lipid synthesis in cancer (we will not cover 
other lipid-independent signal transduction pathways 
from the membrane to the nucleus28,29).
Phosphoinositides: from growth to metastasis. Many 
known oncogenes, such as mutated ERBB, insulin-like 
growth factor-1 (IGF1), c-Kit (stem-cell factor recep-
tor), overexpressed chemokine receptors, mutated Ras, 
BCR–ABL and elevated levels of the proto-oncogene Src, 
to name but a few, provide constitutive input signals to 
PI3K6,30. The finding that the 3-lipid phosphatase PTEN
(phosphatase and tensin homologue deleted on chromo-
some ten) is frequently mutated in numerous late-stage 
tumours finally demonstrated that elevated levels of 
PtdIns(3,4,5)P3 contribute to oncogenesis31,32. PI3KA has 
also been found to be mutated in colon, gastric and breast 
cancer33, and structural studies have recently elucidated 
how key mutations can constitutively activate the PI3KA
complex by relieving the inhibitory action of the p85 
regulatory subunit on the catalytic subunit p110A.
Of the numerous PH-domain-containing proteins 
(see the review by Lemmon in this issue), protein 
kinase B (PKB; also known as Akt) functions as an 
important node to relay signals from PI3K-generated 
PtdIns(3,4,5)P3 during growth and proliferation (FIG. 3;
for reviews see REFS 35,36). PKB/Akt is upregulated or 
mutated in some tumours, and a mutation in the phospho-
inositide-binding domain of PKBA/Akt1 that causes it to 
associate with the plasma membrane and renders it con-
stitutively active has been identified37. PKB/Akt increases 
transcription and translation through the tuberous 
sclerosis complex (TSC), the target of rapamycin (TOR) 
complex-1 (TORC1; REF. 38) and phosphorylation of gly-
cogen synthase kinase-3B (GSK3B	. PKB/Akt-controlled 
regulation of cyclin D1 and class O forkhead box (FOXO)
transcription factors promotes cell-cycle entry, whereas 
PKB/Akt counteracts apoptosis through phosphoryla-
tion of the inhibitor of nuclear factor-KB (IKB) kinase 
(IKK), caspase-9 and the pro-apoptotic factor BAD. 
Elevation of PtdIns(3,4,5)P3 levels also promotes the 
transition to malignancy, as several guanine nucleotide-
exchange factors for Rho GTPases — for example, Vav and 
Tiam — are directed to the membrane by PH domains. 
The cytoskeletal rearrangements that are subsequently 
stimulated enhance cell migration and metastasis39.
Box 4 | Nuclear receptors
Some eicosanoids, as well as fatty acid derivatives and sterol derivatives, signal through nuclear hormone receptors, such 
as the farnesoid X receptor (FXR), liver X receptor (LXR) and peroxisome proliferator-activated receptors (PPARs). All of 
these lipid-sensing receptors heterodimerize with the retinoid X receptor (RXR) to activate a feed-forward metabolic 
cascade that maintains nutrient lipid homeostasis by governing the transcription of a common family of genes involved 
in lipid metabolism, storage, transport and elimination78,143.
The PPARs (A, G, D) were originally identified in Xenopus laevis as receptors that induce peroxisome formation. They are 
activated by polyunsaturated fatty acids, eicosanoids and various synthetic ligands. Consistent with the distinct 
expression pattern of these isoforms, gene-knockout experiments have revealed that each PPAR subtype carries out a 
specific function in fatty acid homeostasis. PPARA-regulated genes function together to coordinate the complex 
metabolic changes that are necessary to conserve energy during fasting and feeding. This isoform is the main target of 
fibrate drugs, a class of amphipathic carboxylic acids that are used in cholesterol disorders as an adjunct to statins, and in 
disorders that feature high levels of triglycerides. PPARG was identified initially as a key regulator in adipogenesis, but it is 
also important in cellular differentiation, insulin sensitization, atherosclerosis and cancer. Ligands for PPARG include fatty 
acids and other arachidonic acid metabolites, antidiabetic drugs and triterpenoids (polyisoprenes containing six isoprene 
units). In contrast to PPARA, PPARG promotes fat storage by increasing adipocyte differentiation and the transcription of 
several important lipogenic genes. PPARD might affect lipid metabolism in peripheral tissue and its ligands include long-
chain fatty acids and carboprostacyclin. Hereditary disorders of all PPAR isoforms have been described and generally 
lead to a loss of function and concomitant lipodystrophy, insulin resistance and/or acanthosis nigricans144.
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Sphingolipids modulate growth and survival. Ceramide 
concentrations increase in response to cellular stress, 
such as DNA damage, disruption of lysosomal com-
partments or exposure to apoptotic stimuli. Although 
ceramide can be synthesized de novo, it is rapidly 
produced from sphingomyelin by the stress-induced 
activation of neutral sphingomyelinase (nSMase) and 
acid sphingomyelinase (aSMase) (BOX 3), which occurs 
rapidly and can lead to apoptosis. Ceramide can promote 
the clustering of death receptors40 and interferes with the 
relay of PI3K signals by activating protein phosphatases, 
such as ceramide-activated protein phosphatase (CAPP) 
(FIG. 3). Depending on the cell type and setting, however, 
ceramide can also mediate cell differentiation, cell-cycle 
arrest, apoptosis and senescence41, or it can be hydrolysed 
by ceramidase to yield sphingosine.
Sphingolipid metabolites have been recognized 
as important modulators of cell survival, cell growth, 
migration and angiogenesis, and therefore have an 
important role in cancer progression. Sphingosine has 
pleiotropic actions, including the ability to attenuate 
signalling by integrins and mitogen-activated protein 
kinase (MAPK). A truncated form of PKCD has been 
described as a sphingosine-dependent protein kinase 
(SDK1). Substrates of SDK1 include 14-3-3 proteins;
phosphorylated 14-3-3 proteins are reported to form 
dimers, which masks their binding sites and renders 
them unable to bind to phosphorylated targets42. For 
example, BAD is phosphorylated by PKB/Akt, and 
is subsequently retained in the cytosol where it is 
inactivated by 14-3-3 proteins. When 14-3-3 proteins 
are phosphorylated, they dimerize and release BAD, 
which permeabilizes the outer mitochondrial mem-
branes (reviewed in REF. 8). From this, it becomes clear 
that binding of 14-3-3 proteins to phosphorylated 
PKB/Akt substrates and SDK1 action on 14-3-3 proteins 
provide an intersection at which increased sphingosine 
intercepts with a branch of PI3K signalling.
Ceramide and sphingosine are mostly antiprolifer-
ative or pro-apoptotic, but they can be reversibly con-
verted, respectively, to C1P by CerK and to S1P by SphK. 
C1P and S1P both promote growth and counteract 
apoptotic stimuli (FIG. 3). C1P positively affects signal-
ling by PKB/Akt, PKA and PKCZ. C1P-mediated phos-
phorylation of PKB/Akt was reported to be sensitive to 
PI3K inhibitors, which places C1P upstream of PI3K43.
The ceramide–C1P and sphingosine–S1P balance thus 
exerts control on PKB/Akt signalling upstream of PI3K 
and downstream of PKB/Akt (through 14-3-3 protein 
dimerization). At the same time, PI3K can operate 
upstream of SphK, as demonstrated in mast cells (FIG. 2).
It is therefore likely that the sphingolipid and phospho-
inositide conversions are linked and cooperate to decide 
over the life or death of a cell. 
Lipid signalling in metabolic syndrome
Lipid signalling is key for the aetiology of inflamma-
tion and cancer, but it also occupies a central role in 
the progression of the metabolic syndrome. The meta-
bolic syndrome is a combination of medical disorders, 
which are probably triggered by high-calorie diets and 
physical inactivity, and result in an increased risk of 
developing cardiovascular disease and diabetes. The 
symptoms that accompany the metabolic syndrome 
include adipocyte proliferation, inflammation, cellular 
stress, increased production of reactive oxygen species 
(ROS) and insulin resistance (FIG. 4). Owing to the drastic 
increase of the incidence of obesity during recent 
decades, obesity and its associated disorders now con-
stitute a serious health threat to western civilization44.
Gaining a more detailed understanding of its aetiology 
is therefore important to identify potential points of 
intervention.
Figure 1 | Mounting walls. Lipid signalling (LS) is altered 
in a multitude of disease states and can dysregulate cell 
function in the immune system to provoke chronic 
inflammation, autoimmune reactions and allergy, 
contribute to cardiovascular disease, or promote tumour 
growth. Reduced rates of lipid signalling are often 
detected in degenerative and metabolic disease. 
The consequences of derailed lipid signalling can be 
therapeutically approached by inhibitors of lipid-modifying 
enzymes or lipid effector proteins (for example, nuclear 
receptors (NucRs)). Here, the width of such a ‘therapeutic 
wall’ — the space covered by a given coloured section 
between the centre (LS) and a respective disease — 
schematically indicates the power of protection that 
therapeutic inhibition of the marked lipid-modifying 
enzymes might provide. Indeed, drugs that target 
peroxisome proliferator-activated receptors (PPARs) or 
other NucRs, and enzymes involved in the generation of 
eicosanoids (phospholipase A2 (PLA2), cyclooxygenase 
(COX), 5-lipoxygenase (5-LO)), as well as sphingosine 
kinase (SphK), phosphatidylinositol 3-kinase (PI3K) 
signalling and sphingomyelinase (SMase) are currently 
developed or already on the market (see the accompanying 
Poster entitled ‘Targeting lipid signalling in disease’). 
Numerous lipid-modifying strategies are currently under 
investigation, but little attention is attributed to the cross-
interactions that occur in the lipid network. A better 
understanding of synergistic lipid actions might generate 
novel strategies for more effective treatment of the 
diseases outlined above.
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Insulin signalling. The insulin signalling pathway is 
central to the metabolic syndrome because obesity 
is often accompanied by insulin resistance and type 2
diabetes. Insulin and IGF receptors belong to the recep-
tor protein tyrosine kinase family and, unlike other 
receptors in this family (which act through ligand-
dependent dimerization and autophosphorylation), 
mainly catalyse tyrosine phosphorylation on docking 
proteins to mediate their signalling. Among other 
substrates, insulin stimulates tyrosine phosphoryla-
tion of insulin receptor substrate (IRS)45,46 proteins. 
This mediates insulin action and is often attenuated in 
systemic insulin resistance, both in animal models and 
in human disease.
Under normal circumstances, IRS phosphorylation is 
linked to the activation of two main signalling pathways: 
first, the PI3K–PKB/Akt pathway, which is responsible 
for most of the metabolic actions of insulin, including 
uptake of glucose by the glucose transporter GLUT4 and 
glycogen synthesis; and second, the Ras–MAPK path-
way, which cooperates with the PI3K pathway to control 
cell growth and differentiation. Control over insulin 
Figure 2 | Lipid signalling in inflammation and allergy. Crosslinking of high-affinity IgE receptors by IgE–antigen 
complexes initiates the phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) on the IgE 
receptor by the action of membrane-bound protein tyrosine kinases (for example, Fyn). Subsequently, Syk, which is 
recruited to phosphorylated ITAMs through its Src homology-2 (SH2) domains, mediates the phosphorylation of adaptor 
molecules such as LAT (linker for activation of T cells), NTAL (non-T-cell activation linker) and GAB2 (GRB2-associated 
binder), which together mediate the recruitment of class IA phosphoinositide 3-kinases (p85–PI3Kc complex). At the 
membrane, PI3K generates phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) from PtdIns(4,5)P2. PtdIns(3,4,5)P3
functions to recruit pleckstrin homology (PH)-containing proteins such as Bruton’s tyrosine kinase (Btk), phospholipase 
CG (PLCG) and GRP1 (general receptor for phosphoinositides-1). When activated by PtdIns(3,4,5)P3, Btk phosphorylates 
PLCG, which cleaves PtdIns(4,5)P2 to form diacylglycerol (DAG) and Ins(1,4,5)P3, completing the first wave of lipid 
signalling. Subsequently, Ins(1,4,5)P3 releases Ca
2+ from internal stores, while phospholipase D (PLD)145,146 and 
sphingosine kinase (SphK) are activated downstream of PI3K. SphK reinforces Ca2+ release, eventually leading to the 
opening of store-operated Ca2+ channels (SOCCs) as soon as the intracellular Ca2+ pools are depleted. The resulting rise 
in the intracellular Ca2+ concentration (indicated by a yellow cloud) marks the full-scale activation of mast cells, and 
triggers degranulation of histamine-containing granules, as well as the production of prostaglandins (PGs) and 
leukotrienes (LTs) by the combined actions of cytosolic PLA2 (cPLA2), prostaglandin H2 synthase (PGH2S) and 
5-lipoxygenase (5-LO). PGs, LTs and sphingosine-1-phosphate (S1P) exit the cell through transmembrane channels (for 
example, S1P through the ATP-binding cassette transporter ABCC1) and act on G protein-coupled receptors (GPCRs) 
that relay signals to effectors including PLCB and PI3KG. AA, arachidonic acid; ARF6, ADP-ribosylation factor-6; 
FLAP, 5-LO activating protein; PA, phosphatidic acid; PC, phosphatidylcholine; SHIP1, SH2-domain-containing inositol 
5-phosphatase-1. 
© 2008 Nature Publishing Group
7
ht
tp
://
do
c.
re
ro
.c
h
TSC2
ERcyt
17E
17E
nSMase
aSMase
CAPP
Mitochondrial
damage Apoptosis Fatal tumour Metastasis
Contact
independence Proliferation Cellular growth
Caspase cascade
Cyt c release
Actin
motility
Cell cycle,
survival
Translation,
protein synthesisCytokinesisAngiogenesis
Vasodilation
eNOS
OH
N
Cer
PKB Rho Rho
Rictor
mLST8 Rheb FKBP12
SIN1
PKCCycD1
NF-B
FOXO
BAD
CASP9
GEF
PtdIns(3,4,5,)P3 PKB
PDK1
PKB
CerK
C1P
S1P
S1P
P
N
P
P
N
N
P
N
N
O
H
N
Cer
SM
Cer Cer
TRADD TRADD
FAN
PTEN
TSC1FADD ERK
SphK
ERcyt
ERcyt
p85
PI3Kc
p85
PI3Kc
TRAF2
Caspases
NSD
DD
P
N
N
SM
Cer
Sph
OH
N
OH
NH2 NH2
?
Ras
PLC
SH2
Ca2+
VEGFTNF GF
17E
PP P
P
P P
P
m
TO
RC
2
m
TO
RC
1
Rictor
mLST8
mTOR
FRB
mTOR
P
P
P
PLD2X
PC
Rapa
?
?
?
T308
S473
Ab
X
Translocation
Interaction
Indirect action
Conversion
Activation
Inhibition
PH domain
PX domain
Nature Reviews | Molecular Cell Biology
ABCC1
S1PR
PA
PtdIns(3,4,5)P3PtdIns(4,5)P2
pTyr
pTyr-X-X-Met
SH2 domain
Phosphate
SphK
SH2
P
signalling is achieved by an autoregulatory feedback 
loop whereby the S6 kinase-1 (S6K1), a downstream 
effector of mTOR, inhibits upstream elements (a process 
known as homologous desensitization47,48). Alternatively, 
signals from apparently unrelated pathways can inhibit 
insulin signalling through heterologous desensitization 
to coordinate catabolic processes with, for example, 
cellular stress or tissue inflammation.
Lipids and insulin resistance. One of the key causes 
of metabolic syndrome is the constant oversupply of 
energy-rich nutrients — particularly fatty acids, but also 
carbohydrates and proteins or amino acids. Elevated 
plasma levels of fatty acids alone, however, are suffi-
cient to induce insulin resistance and to activate a pro-
inflammatory response49. The availability of free fatty 
acids is sensed by PPARs, which are nuclear receptors 
Figure 3 | Pro- and anti-tumorigenic signals originate from membranes. Growth factor (GF) receptors, cytokine 
and chemokine receptors and oncogenes trigger several signalling pathways that contribute to cancer progression. 
Only input signals that trigger lipid-modifying or lipid-binding proteins are shown. Class IA phosphatidylinositol 3-kinases 
(shown as the p85–PI3Kc complex) can be activated by GF receptors directly, or by their phosphorylated substrates (not 
shown; for a review see REF. 5). Protein kinase B (PKB/Akt) is then translocated to PI3K-generated phosphatidylinositol-
3,4,5-trisphosphate (PtdIns(3,4,5)P3) at the plasma membrane, where PKB/Akt is phosphorylated on Thr308 by 
phosphoinositide-dependent kinase-1 (PDK1) and on Ser473 by mammalian target of rapamycin complex-2 (mTORC2) to 
gain its full activity. Through the phosphorylation of TSC2 (tuberin) in the TSC2–TSC1 (hamartin) complex, PKB/Akt then 
releases the block on the GTPase Rheb to activate TORC1. TORC1 is a major relay to transcription and protein synthesis, 
and can be inhibited by the rapamycin (rapa)–FKBP12 complex. In cells that express the oestrogen receptor (ERcyt), the 
addition of an ER ligand (17B-estradiol (17BE)) has been reported to induce the formation of a PI3K–ER complex. Similarly, 
17BE was shown to induce sphingosine kinase (SphK) activity, which explains the cytosolic growth-promoting actions of 
ER. The vascular endothelial growth factor (VEGF)-induced activity of ERK can phosphorylate and activate SphK147, which 
generates sphingosine-1-phosphate (S1P). This is especially relevant in endothelial cells, in which S1P supports signalling 
by VEGF receptors. This process enforces a feed-forward loop that supports angiogenesis. Counteracting GF signalling, 
both ceramide (Cer) and sphingosine (Sph) can trigger pro-apoptotic events. Ceramide promotes the lateral association of 
death receptors that contain death domains (DD) and enforces, for example, TNFA receptor signalling to the caspase 
cascade. Through the neutral sphingomyelinase (nSMase) activating domain (NSD), the TNFA receptor augments the 
conversion of sphingomyelin (SM) to ceramide. At the same time, ceramide and sphingosine activate protein 
phosphatases (for example, ceramide-activated protein phosphatase (CAPP)), which attenuate PKB/Akt activation by the 
PI3K pathway. Whereas these processes promote apoptosis, the TNFA receptor also has a growth-promoting output 
towards SphK activation. ABCC1, ATP-binding cassette subfamily C member-1 transporter; C1P, ceramide-1-phosphate; 
CASP9, caspase-9; CerK, ceramide kinase; CycD1, cyclin D1; Cyt c, cytochrome c; ERK, extracellular signal-regulated 
kinase; FAN, factor associated with nSMase; FADD, Fas-associated death domain; FOXO, class O forkhead box 
transcription factor; NF-KB, nuclear factor-KB; PC, phosphatidylcholine; PLC, phospholipase C; TRADD, tumour necrosis 
factor receptor-associated death domain protein.
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that control fatty acid storage, degradation and adipo-
cyte differentiation. Another important group of mole-
cules that coordinates lipid responses in adipocytes 
includes lipid chaperone proteins, such as fatty acid 
binding proteins (FABPs). Animals that lack FABP4 and 
FABP5 exhibit a fatty acid-resistant phenotype similar 
to that of mice and humans that are given PPARG lig-
ands, indicating that FABPs and PPARs might function 
in similar pathways to control the biological effects of 
lipids50,51. Remarkably, mice lacking FABP4 or FABP5, 
or animals treated with a small-molecule inhibitor of 
FABP4, are protected against almost every aspect of the 
metabolic syndrome, including visceral obesity, insulin 
resistance, hepatosteatosis and atherosclerosis50,52–54.
Although our understanding of the precise mechanisms 
that underlie FABP action is incomplete, FABPs are 
known to modulate lipid composition and fluxes of fatty 
acids into newly synthesized lipids, which is probably a 
crucial feature of their biological function.
One lipid that is overproduced as a result of the 
increase in fatty acid concentrations is ceramide. 
Ceramide activates protein phosphatase-2A (PP2A), 
which, in turn, inactivates PKB/Akt and thereby atten-
uates the insulin response55. Moreover, recent results 
suggest that PKCZ, which is also activated by ceramide, 
inhibits PKB/Akt translocation to the cell membrane by 
phosphorylating Thr34 within the PH domain of PKB/
Akt. In addition, ceramide blocks plasma membrane 
Figure 4 | Excess fatty acids induce insulin resistance and metabolic syndrome. Insulin controls glucose uptake 
through tyrosine phosphorylation of insulin receptor substrate (IRS) proteins. Activation of phosphatidylinositol 3-kinase 
(PI3K) and generation of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) activates protein kinase B (PKB/Akt), 
which, in turn, supports recycling of the glucose (Glc) transporter GLUT4 to the plasma membrane. The mammalian target 
of rapamycin complex-1 (mTORC1) coordinates protein synthesis with available nutrients and energy, and desensitizes 
the pathway through inhibitory phosphorylation of IRS. Excess levels of fatty acids increase the synthesis of ceramide and 
inhibit the activity of PKB/Akt through protein phosphatase-2A (PP2A) and protein kinase-Z (PKCZ). Excess fatty acids also 
activate the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-G to induce adipocyte differentiation, 
which is dampened by the fatty acid-binding protein-4 (FABP4). Excess fatty acids induce increased lipid synthesis, further 
raising the levels of diacylglycerol (DAG), acyl CoA and triacylglycerol (TG). Elevated levels of DAG and acyl CoA result 
in activation of PKCD and PKCQ and the subsequent induction of a pro-inflammatory programme, which culminates in 
the activation of nuclear factor-KB (NF-KB). The increased lipid load in the endoplasmic reticulum induces a stress 
response and leads to the production of reactive oxygen species (ROS). This leads to the activation of c-Jun N-terminal 
kinase (JNK) and induction of activator protein-1 (AP-1). Both molecules inhibit PPARG, which further increases the 
detrimental action of elevated levels of fatty acids, and induces the synthesis of pro-inflammatory cytokines such as 
tumour necrosis factor-A (TNFA). This response is further amplified by activation of the Toll-like receptor-4 (TLR4) and its 
effectors by elevated plasma fatty acid levels, which then results in chronic inflammation. Both inhibitor of NF-KB kinase 
(IKK)-B and JNK further desensitize insulin responsiveness through inhibitory serine phosphorylation of IRS.  
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translocation of the PtdIns(3,4,5)P3-binding protein 
general receptor for phosphoinositides-1 (GRP1), which 
catalyses guanine nucleotide exchange on ADP-ribo-
sylation factors (ARFs) and thereby interferes with the 
PI3K-dependent regulation of vesicular transport and 
membrane remodelling55. Ceramide therefore attenuates 
insulin signalling, and thereby contributes to insulin 
resistance, through multiple pathways.
Lipid accumulation induces cellular stress. The 
accumulation of excess lipid, in particular saturated 
fatty acids and sterols, might induce cellular damage 
through stress on the membranes of lipid-metabolizing 
organelles, especially the endoplasmic reticulum (ER) 
and possibly mitochondria56–58. Under these conditions, 
the ER activates a complex response system known 
as the unfolded protein response (UPR) to restore the 
functional integrity of the organelle59. Remarkably, 
orally active chemical chaperones that stabilize pro-
tein conformation and improve ER folding capacity 
can alleviate ER stress and can function as potent 
antidiabetic agents, restoring glucose homeostasis 
in mouse models of type 2 diabetes60. The ER is also 
a major source of ROS and, consequently, oxidative 
stress61,62. Oxidative stress is emerging as a feature of 
obesity and an important factor in the development 
of insulin resistance, and is frequently associated with 
mitochondrial dysfunction63–65.
Inflammation in metabolic syndrome. Lipid-derived 
signals, particularly eicosanoids and S1P, are important 
mediators of the inflammatory response. Inflammation 
itself, however, is a key feature of obesity and type 2
diabetes, as has become clear during the past decade66.
Infiltration of adipose tissue by immune cells such as 
macrophages has recently been described in obese mice 
and humans67,68. Chronic inflammation is character-
ized by abnormal cytokine production69, and tumour 
necrosis factor-A (TNFA) has been found to be over-
expressed in the adipose tissue of obese mice70. TNFA
is a pro-inflammatory cytokine that activates various 
signal transduction cascades, including many of the 
pathways that are discussed below as crucial inhibi-
tors of insulin action. In obese mouse models with a 
targeted mutation in the gene encoding TNFA insulin 
sensitivity and glucose homeostasis improved, which 
confirms that this inflammatory response has a vital 
role in the regulation of insulin action71,72. TNFA is also 
overexpressed in the adipose and muscle tissue of obese 
humans, and when exogenously administered, causes 
insulin resistance73.
Elevated plasma levels of free fatty acids can also 
directly elicit a pro-inflammatory response by binding 
to Toll-like receptors (TLRs). TLRs belong to a family 
of pattern-recognition receptors that are essential in 
the innate immune system for activating the nuclear 
factor-KB (NF-KB)-dependent pro-inflammatory sig-
nalling pathway in response to microbial pathogens 
or nutrients, particularly fatty acids74. Although TLR4 
recognizes lipopolysaccharide from Gram-negative bac-
teria as a ligand, it is also activated by free fatty acids75.
Furthermore, mice that lack TLR4 are substantially 
protected from the ability of systemic lipid infusion to 
suppress insulin signalling in muscle and from insulin-
mediated changes in systemic glucose metabolism76.
Lipids coordinately regulate metabolic, innate 
immune and inflammatory processes77. Several trans-
cription factors, particularly those of the PPAR and liver 
X receptor (LXR) families, seem to be crucial to integrate 
input from pathways involved in these processes. The 
ligands of all three PPAR family members suppress 
the production of pro-inflammatory cytokines, mostly 
by suppressing NF-KB14,78,79.
How obesity impinges on insulin signalling. Mounting 
evidence indicates that activation of c-Jun N-terminal 
kinase (JNK), IKK and conventional PKC is central 
to the development of insulin resistance in response to 
obesity — mediated by the aforementioned fatty acid-
induced ER stress, ROS production, TLR activation 
and inflammatory signalling by TNFA. JNK, IKK and 
PKC have all been reported to inhibit insulin action by 
phosphorylating IRS1 on serine80–82. Serine phospho-
rylation of IRS1 disrupts insulin-receptor signalling 
through several distinct mechanisms and blocks insulin 
action83,84.
JNK is activated after exposure to cytokines, such as 
TNFA, as well as by free fatty acids through the TLR 
pathway and internal cues such as ER stress, all of which 
might underlie its obesity-induced activity60,80,85. There 
is a striking increase in JNK activity at crucial metabolic 
sites such as adipose and liver tissue in mouse models 
of obesity86. Most importantly, JNK deficiency protects 
mice from insulin resistance, fatty liver and diabetes86,
which implies that JNK inhibition might be a promising 
therapeutic avenue for diabetes87–89.
Similarly, IKK is also activated through TLR4 and 
TNFA. Mice that are heterozygous for a loss-of-function 
mutation in IKKB are partly protected from obesity-
induced insulin resistance, and inhibition of IKKB by high-
dose salicylates improves insulin action in experimental 
models and humans90.
PKC is the third important mediator between meta-
bolic pathways and the inflammatory response49,77,91.
Fatty acid metabolites such as fatty acid coenzyme A and 
DAG can activate PKCQ in muscles or PKCD in the liver 
and inhibit insulin action49,77. Mice that are deficient in 
PKCQ are protected against fatty acid-induced insulin 
resistance, which confirms the contribution of this kinase 
to metabolic regulation in vivo91. At a mechanistic level, 
PKCQ is known to activate IKK and might contribute to 
insulin resistance through this pathway.
JNK, IKK and PKC also exert powerful effects on 
gene expression, including the promotion of inflamma-
tory gene expression through the activation of activator 
protein-1 (AP-1) complexes and NF-KB. This activation 
results in downregulation of PPARG-dependent genes, 
possibly through competition for common activators, 
thus inhibiting adipocyte differentiation and clearing of 
circulating fatty acids92. Notably, JNK–AP-1 and IKK–
NF-KB are linked to components that sense and mediate 
ER stress and oxidative stress93–95.
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Taken together, free fatty acids seem to have a key 
role in inducing and mediating many of the symptoms 
that accompany the metabolic syndrome, including 
adipocyte proliferation, inflammation, cellular stress, 
increased ROS production and insulin resistance. A 
better characterization of the precise mechanisms by 
which these elevated levels of fatty acids result in the 
activation of key kinases such as JNK and PKC, and how 
they cause insulin resistance, will open new therapeutic 
opportunities to attenuate some of the pathologies and 
improve insulin responsiveness.
Therapeutic opportunities
Lipids in inflammation: points of interception. Strategies 
to attenuate chronic inflammation and allergy involve 
the interception of immune cell migration to target 
tissues and/or the blockage of signalling events, lead-
ing to the release of inflammatory mediators. PI3KG,
the only class IB PI3K isoform, is activated by BG
subunits of trimeric G proteins that are dissociated by 
GPCRs to produce transient, but massive, elevations 
of PtdIns(3,4,5)P3. This lipid kinase integrates multi-
ple signals from chemokines, complement fragments, 
formylated bacterial peptides and other stimuli, and was 
shown to be essential for chemokine-induced leukocyte 
migration in vivo96–98. Therefore, PI3KG has become the 
subject of impressive pharmacological efforts as a target 
to treat inflammatory disease5,99. PI3KG inhibitors (for 
example, AS605240) have shown therapeutic effects in 
mouse models of rheumatoid arthritis100 and systemic 
lupus erythematosus101, in which the compounds atten-
uated the migration of neutrophils and lymphocytes, 
respectively, into inflamed tissue.
As outlined above, the PI3KD isoform is activated 
downstream of a protein tyrosine cascade that emerges 
from Ig receptors. In the absence of PI3KD activity — for 
example, in mice with a catalytically inactive p110D cata-
lytic subunit17, or those treated with the PI3KD inhibitor 
IC87114 (REF. 102) — degranulation of mast cells is atten-
uated. As a result, these mice are protected against the 
deleterious effects of IgE and allergen exposure. Histamine 
acts on endothelia to increase vascular permeability and 
dilation, causing a drop in body temperature and blood 
pressure, which can result in a fatal anaphylactic shock.
Surprisingly, elimination of the PI3KG isoform pro-
tects mice against IgE–allergen-mediated anaphylaxis, as 
described for the loss of PI3KD activity above. PI3KG
has not directly been linked to IgE–allergen-triggered 
clustering of FcERI, but the IgE–allergen causes the 
release of adenosine from mast cells, which signals 
through GPCRs to activate PI3KG; the resulting peak in
PtdIns(3,4,5)P3 is essential for the in vivo responsiveness 
of mast cells103. In addition, genetic evidence suggests 
that modulation of PI3KG activity could be beneficial 
in cardiovascular disease104, and dual PI3KG/D inhibitors 
(for example, TG100-115) have entered clinical trials 
for myocardial infarction105. Owing to the above, PI3KG
inhibitors have been enthusiastically dubbed the ‘aspi-
rin of the twenty-first century’99, but single-specificity 
inhibitors for PI3KG and PI3KD still await validation for 
the treatment of human disease.
By contrast, a high degree of validation and feasibility 
has been reached for targeting the sphingosine kinase 
pathway. FTY720 (fingolimod), when phosphorylated 
by sphingosine kinase, functions as an S1P receptor 
agonist and targets four (out of the five) S1P receptors. 
FTY720 interferes with the exit of lymphocytes from 
lymph nodes, and therefore attenuates autoimmune 
disease (for example, multiple sclerosis)106–108, organ 
rejection in transplantation, and is under considera-
tion for other inflammatory and allergic conditions27,109.
S1P1-specific agonists (SWE2871; REF. 110) and anta-
gonists111 have helped to define S1P1 as the main target 
of S1P on lymphocytes. S1P1 antagonists also modulate 
endothelial permeability112, and thus also show some 
adverse effects.
Phospholipases A2, C and D have established roles 
in inflammation and allergy. Numerous efforts to tar-
get these enzymes have generated useful experimental 
inhibitors (see accompanying Poster ‘Targeting lipid 
signalling in disease’), but no marketable drugs so far. 
Overall, PLA2 levels are modulated by corticosteroids113.
Downstream of cPLA2, the cyclooxygenase (COX) 
activity of prostaglandin H2 synthase is a classic target 
of NSAIDs. Treatment of rheumatoid disease with the 
selective COX2 inhibitor rofecoxib (Vioxx) was associ-
ated with serious cardiovascular complications114, which 
raised fears that this result was coupled to COX2 as a 
drug target in general.
An alternative to inhibiting COX activity is targeting 
prostaglandin and thromboxane receptors. This inhi-
bition has been achieved with ramatroban, marketed 
for allergic rhinitis, which blocks the TP receptor (this 
receptor binds thromboxane A2) and the chemoattract-
ant receptor-homologous molecule that is expressed on 
Th2 lymphocytes (CRTH2; receptor for prostaglandin 
D2) in parallel115. Modulation of leukotriene action 
has also been shown to be effective against asthma and 
allergic rhinitis: zileton targets 5-LO with a limited 
potency, whereas montelukast, pranlukast and zafirlu-
kast interfere with the action of cysteinyl leukotrienes 
(leukotrienes C4, D4 and E4) on cysteinyl leukotriene-1 
and -2 receptors116,117.
It is evident, therefore, that modulation of extra-
cellular and intracellular lipid signalling is beneficial 
in the treatment of inflammation, autoimmunity and 
allergy. Novel strategies are in progress; it seems that it 
is often not necessary to completely block the output of 
a given lipid pathway, but that partial attenuation of the 
lipid network is sufficient to generate a beneficial effect 
for the patient.
Targeting lipids in cancer. Presently, the PI3K pathway 
can be therapeutically targeted at the level of TORC1 by 
rapamycin (sirolimus and its derivatives temsirolimus 
and everolimus; FIG. 3). Tumours with constitutively 
elevated PtdIns(3,4,5)P3 (for example, owing to loss of 
PTEN or because of mutations in PI3KA	 are especially 
sensitive to rapamycin118, but an important action of 
rapamycin-based drugs seems to be their effect on 
endothelial cells and angiogenesis38. Limited information 
is available concerning the in vivo isoform-specificity 
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of novel PI3K inhibitors, and molecules with proven 
anti-tumour activity in xenograft models (PI-103 
(REFS 119,120) and ZSTK474 (REF. 121)) are broad-
spectrum PI3K inhibitors, and might also owe some 
of their action to the inhibition of mammalian TOR 
(mTOR). NVP-BEZ235 has recently entered clinical 
trials as a treatment for solid tumours122. It is not clear 
whether or not targeting single PI3K isoforms will 
be successful in cancer therapy, and whether PI3K 
inhibitors will be effective as single agents. Collective 
data indicate that they will be of value in combination 
therapy: PI3K inhibitors have been shown to reverse 
resistance to trastuzumab (herceptin, a monoclonal 
antibody directed against ERBB2), which was caused 
by the loss of PTEN123.
As explained above, S1P is of major importance in 
the migration of lymphocytes out of secondary lym-
phatic organs. In cancer, S1P promotes cell growth and 
survival, angiogenesis, vascular maturation and medi-
ates cell migration (FIG. 3). Using a monoclonal antibody 
with high affinity for S1P, Visentin and colleagues124
have demonstrated that providing a sink for S1P is 
sufficient to block angiogenesis and endothelial cell 
migration in response to vascular endothelial growth 
factor (VEGF) and basic fibroblast growth factor. The 
fact that the growth of an S1P-insensitive melanoma 
xenograft was inhibited indicates that removal of S1P 
hits a central signalling hub, which could prevent angio-
genesis in various cancers (for an excellent comment see 
REF. 125). To further clarify the mechanism of action of 
S1P removal, it would be interesting to compare the S1P 
antibodies with SphK inhibitors, which also have anti-
proliferative activity126, and are also expected to cause 
a build-up of intracellular sphingosine. An alternative 
strategy for lowering S1P levels might be the activation 
of S1P lyase127, an ER-localized enzyme, which cleaves 
S1P to yield ethanolamine phosphate and hexadecanal. 
Indeed, S1P lyase was reported to promote apoptosis 
and to be downregulated in colon cancer128.
An action that is independent of FTY720 phos-
phorylation was reported in chronic myelogenous 
leukaemia (CML) cells, in which the fusion protein 
BCR–ABL drives proliferation: here, FTY720 triggered 
the activation of the protein phosphatase PP2A and, 
consequently, apoptosis129. Interestingly, PP2A regulates 
PKCs and PKB/Akt, providing another crossover point 
with PI3K signalling.
Sphingolipid and PI3K signalling not only control 
the same molecular targets, but the pathways also 
converge at the level of physiological responses. As an 
example, S1P (probably through S1P receptors130) and 
PtdIns(3,4,5)P3 (through PKB/Akt) both lead to the 
activation of endothelial nitric oxide synthase (eNOS) 
and the release of nitric oxide (NO∙) radicals. NO∙ acts 
through the NO–cyclic GMP pathway and, to some 
degree, through the formation of reactive nitrogen 
species to dilate blood vessels, decrease the blood–
tumour barrier and to promote angiogenesis. This is 
clearly underlined by the lack of VEGF-induced angio-
genesis in the absence of eNOS (reviewed in REF. 131). 
Based on the above, and on the fact that PI3K also acts 
downstream of the VEGF receptor, it becomes clear 
how PI3K inhibitors develop their anti-angiogenic 
activity120.
Understanding the sphingolipid and polyphospho-
inositide balance and their interconnection might 
therefore provide novel opportunities to achieve a 
stringent control of proliferation and growth of tumour 
cells and endothelia in angiogenesis, which is needed 
to interfere with the dissemination of adaptable and 
motile cancer cells.
Targeting metabolic syndrome. Given the complex aeti-
ology of the metabolic syndrome, preventing the disease 
and its progression is a challenging task that must be 
addressed from various angles, preferably starting with 
the prevention of the intake of excess nutritional lipids 
to tame chronic inflammatory responses. Although a 
simple measure, it is often not applicable. Targeting 
the hormone-sensitive lipase (HSL), which liberates 
free fatty acids for cellular uptake, is an option that has 
been realized with the use of orlistat. Similarly, small-
molecule inhibitors of FABP4 have produced promising 
results in preventing metabolic syndrome in high-fat 
diet animal models, and raises hopes that this strategy 
might advance further50,52–54. Cellular stress that is 
caused by an excess of fatty acids can be alleviated using 
orally active chemical chaperones that act to stabilize 
protein conformation and improve the protein folding 
capacity of the ER. Such small molecular chaperones 
have indeed been proven to restore glucose homeostasis 
in preclinical models of type 2 diabetes60.
Nutrient overload also triggers alterations in gene 
expression, which are mediated by nuclear receptors as 
described above. Here, agonists for PPARs have a proto-
typic role, and rosiglitazone has been successfully used 
to manage insulin resistance. However, this treatment 
comes at a price because rosiglitazone is associated with 
an increased risk of myocardial infarction132.
Both the inflammatory branch of metabolic dis-
ease and insulin resistance can eventually be targeted 
by JNK. JNK deficiency has been reported to protect 
mice from insulin resistance, fatty liver and diabetes86,
and inhibition of JNK is considered to be a promising 
therapeutic avenue87–89. Similarly, mouse models har-
bouring null mutations in IKKB have validated that 
this kinase impacts insulin signalling, and inhibition of 
IKKB by high-dose salicylates improves insulin action 
in experimental models and humans90.
Long-term complications in type 2 diabetes, such as 
diabetes-induced retinopathy, are the subject of clinical 
trials with PKCB inhibitors (LY-333531; also known as 
ruboxistaurin)133,134. It has also been claimed that PKCB
null mice — although they are hyperphagic — display an 
increased insulin sensitivity and fatty acid oxidation135. If 
applicable to humans, pharmacological manipulation of 
metabolic turnover could provide ways to lower visceral 
fat mass without reducing caloric intake. Whether this 
is desirable is, of course, another question, and maybe 
the best answer to this was given ~200 years ago by 
J. A. Brillet-Savarin: “Tell me what you eat, and I will tell 
you what you are”.
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Conclusions and perspectives
From the data presented above, it is clear that pathways 
that generate and respond to signalling lipids such as 
activation of PI3K, sphingolipid turnover, eicosanoid 
production and PPAR-dependent gene regulation have 
important roles in inflammation, cancer and metabolic 
syndrome. Lipid signalling events are shared among 
these different diseases; for example, metabolic syn-
drome involves inflammatory processes to develop into 
type 2 diabetes, atherosclerosis or cardiovascular disease; 
and cancer utilizes increased lipid signalling to progress 
from benign to malignant stages.
Lipid signalling cascades are complex, sometimes 
redundant and highly interconnected. Nevertheless, 
signalling lipid-generating enzymes have been and are 
still being targeted pharmacologically to alleviate the 
symptoms or even progression of the different diseases. 
In cases in which the modulation of one lipid signalling 
pathway does not suffice therapeutically, combinatorial 
treatments are being considered and may prove effective. 
Although such approaches can be explored experimen-
tally in vivo or even clinically, the data to predict patient 
benefit are relatively scarce. This poor predictability of 
the in vivo response is, at least in part, caused by our 
incomplete understanding of the dominant and permis-
sive properties of interacting lipid signalling pathways. 
In addition, the tools that are available to follow the 
dynamics of agonist-modulated production of the lipid 
signal, to monitor the precise chemical modification 
of the lipid and its spatial organization are technically 
limited and hamper a more comprehensive description 
of these pathways and their interconnectivity. Unlike 
proteins, the function of which can largely be addressed 
individually, lipid actions are frequently masked by a 
large ‘steady-state’ mass represented by the structural 
lipids in the membrane, which makes it difficult to 
detect the transient lipid signal. Fluorescent probes 
— mostly based on lipid-binding protein domains such 
as PH domains — have been established for phospho-
inositides136, but many of the other lipid mediators are 
still difficult to trace. Further advances in these fields and 
their integration for therapeutic use are, therefore, likely 
to benefit significantly from improved time-resolved 
methods to monitor lipid signals.
If this is achieved, we can substantiate what becomes 
apparent in this review: the lipid signalling pathways, 
studied in-depth in isolation elsewhere, do not operate 
independently, but mostly act in concert to control cell 
death, stasis or proliferation and cellular activity. Lipid 
signalling is context dependent and understanding the 
semantics of this molecular language is a challenge for 
the future.
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